These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22816430)

  • 1. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.
    Kaneko MK; Kunita A; Abe S; Tsujimoto Y; Fukayama M; Goto K; Sawa Y; Nishioka Y; Kato Y
    Cancer Sci; 2012 Nov; 103(11):1913-9. PubMed ID: 22816430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
    Kaneko MK; Abe S; Ogasawara S; Fujii Y; Yamada S; Murata T; Uchida H; Tahara H; Nishioka Y; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.
    Kato Y; Kunita A; Abe S; Ogasawara S; Fujii Y; Oki H; Fukayama M; Nishioka Y; Kaneko MK
    Oncotarget; 2015 Nov; 6(34):36003-18. PubMed ID: 26416352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Core-Fucose-Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies.
    Kaneko MK; Ohishi T; Nakamura T; Inoue H; Takei J; Sano M; Asano T; Sayama Y; Hosono H; Suzuki H; Kawada M; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):167-174. PubMed ID: 33085938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.
    Abe S; Morita Y; Kaneko MK; Hanibuchi M; Tsujimoto Y; Goto H; Kakiuchi S; Aono Y; Huang J; Sato S; Kishuku M; Taniguchi Y; Azuma M; Kawazoe K; Sekido Y; Yano S; Akiyama S; Sone S; Minakuchi K; Kato Y; Nishioka Y
    J Immunol; 2013 Jun; 190(12):6239-49. PubMed ID: 23690472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S; Kaneko MK; Tsuchihashi Y; Izumi T; Ogasawara S; Okada N; Sato C; Tobiume M; Otsuka K; Miyamoto L; Tsuchiya K; Kawazoe K; Kato Y; Nishioka Y
    Cancer Sci; 2016 Sep; 107(9):1198-205. PubMed ID: 27294401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies.
    Nakazawa Y; Takagi S; Sato S; Oh-hara T; Koike S; Takami M; Arai H; Fujita N
    Cancer Sci; 2011 Nov; 102(11):2051-7. PubMed ID: 21824222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
    Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
    Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.
    Kaneko MK; Yamada S; Nakamura T; Abe S; Nishioka Y; Kunita A; Fukayama M; Fujii Y; Ogasawara S; Kato Y
    Cancer Med; 2017 Apr; 6(4):768-777. PubMed ID: 28332312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.
    Ukaji T; Takemoto A; Shibata H; Kakino M; Takagi S; Katayama R; Fujita N
    Cancer Sci; 2021 Jun; 112(6):2299-2313. PubMed ID: 33735501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of P38Bf, a Core-Fucose-Deficient Mouse-Canine Chimeric Antibody Against Dog Podoplanin.
    Kato Y; Mizuno T; Yamada S; Nakamura T; Itai S; Yanaka M; Sano M; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2018 Nov; 37(5):218-223. PubMed ID: 30362926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2.
    Ogasawara S; Kaneko MK; Price JE; Kato Y
    Hybridoma (Larchmt); 2008 Aug; 27(4):259-67. PubMed ID: 18707544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain.
    Kato Y; Kaneko MK; Kuno A; Uchiyama N; Amano K; Chiba Y; Hasegawa Y; Hirabayashi J; Narimatsu H; Mishima K; Osawa M
    Biochem Biophys Res Commun; 2006 Nov; 349(4):1301-7. PubMed ID: 16979138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Monoclonal Antibody LpMab-7 Recognizing Non-PLAG Domain of Podoplanin.
    Oki H; Kaneko MK; Ogasawara S; Tsujimoto Y; Liu X; Sugawara M; Takakubo Y; Takagi M; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):174-80. PubMed ID: 26090595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
    Kato Y; Kaneko MK
    Sci Rep; 2014 Aug; 4():5924. PubMed ID: 25080943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy evaluation of radioimmunotherapy with
    Sudo H; Tsuji AB; Sugyo A; Saga T; Kaneko MK; Kato Y; Higashi T
    Cancer Sci; 2019 May; 110(5):1653-1664. PubMed ID: 30801908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.
    Kato Y; Vaidyanathan G; Kaneko MK; Mishima K; Srivastava N; Chandramohan V; Pegram C; Keir ST; Kuan CT; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2010 Oct; 37(7):785-94. PubMed ID: 20870153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet-activating factor podoplanin: from discovery to drug development.
    Takemoto A; Miyata K; Fujita N
    Cancer Metastasis Rev; 2017 Jun; 36(2):225-234. PubMed ID: 28674748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis.
    Sekiguchi T; Takemoto A; Takagi S; Takatori K; Sato S; Takami M; Fujita N
    Oncotarget; 2016 Jan; 7(4):3934-46. PubMed ID: 26684030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.